DLD Asset Management Reduces Eli Lilly Stake

Institutional investor sells off 87.5% of its Eli Lilly holdings in Q3

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

DLD Asset Management LP reduced its position in Eli Lilly and Company (NYSE:LLY) by 87.5% in the third quarter, according to the company's latest 13F filing with the Securities & Exchange Commission. The institutional investor now owns just 265 shares of the pharmaceutical company's stock, down from 2,116 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs and therapies. Institutional investors closely monitor and adjust their positions in Lilly, so this reduction in DLD Asset Management's stake could signal a shift in sentiment around the stock.

The details

According to the 13F filing, DLD Asset Management sold 1,851 shares of Eli Lilly, leaving it with a much smaller position of just 265 shares worth approximately $202,000 at the end of the third quarter. The filing does not provide specific reasons for the sell-off, but it comes as Eli Lilly's stock has seen significant gains over the past year, rising from around $623 per share to over $990 per share.

  • DLD Asset Management filed its 13F report for the third quarter of 2026.

The players

DLD Asset Management LP

An institutional investment firm that manages a portfolio of stocks, including a previous position in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and commercializes a range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

This reduction in DLD Asset Management's Eli Lilly holdings suggests the firm may be taking profits after the stock's strong performance over the past year. However, Eli Lilly remains a closely watched pharmaceutical company, and institutional investors will likely continue to monitor and adjust their positions in the stock.